Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.59 |
| ▸ | CTSK | P43235 | 2/20 | 0.59 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 10/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | REN | P00797 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7316871 | 0.95 | CTSS (0.55) | CTSSCTSKCTSLCTSBBACE1 | |
| SCHEMBL10727619 | 0.95 | CTSS (0.62) | CTSSCTSKCTSLCTSBBACE1 | |
| SCHEMBL7316868 | 0.93 | CTSS (0.53) | CTSSCTSKCTSLCTSBBACE1 | |
| SCHEMBL7320746 | 0.93 | CTSS (0.53) | CTSSCTSKCTSLCTSBBACE1 | |
| SCHEMBL17326876 | 0.90 | CTSS (0.56) | CTSSCTSKCTSLCTSBBACE1 | |
| SCHEMBL11020537 | 0.89 | CTSS (0.55) | CTSSCTSKCTSLCTSBBACE1 | |
| SCHEMBL10787770 | 0.89 | CTSS (0.55) | CTSSCTSKCTSLCTSBBACE1 | |
| SCHEMBL10787765 | 0.89 | CTSS (0.55) | CTSSCTSKCTSLCTSBBACE1 | |
| SCHEMBL352156 | 0.88 | CTSS (0.68) | CTSSCTSKTSHR | |
| SCHEMBL478905 | 0.88 | CTSS (0.68) | CTSSCTSKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130889-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2026-05-14 | — | — | US | disclosed |
| US-12433873-B2 | Microtubule polymerization inhibitor prodrugs and methods of using the same | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4403171-A2 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | University of Maryland, Baltimore (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-3641741-B1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230241034-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | UNIV MARYLAND (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230220339-A1 | T CELL, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF | Benethera (Beijing) Biotechnology Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-11622960-B2 | Microtubule polymerization inhibitor prodrugs and methods of using the same | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-04-11 | — | — | US | disclosed |
| EP-4151721-A1 | T CELL, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF | Benethera (Beijing) Biotechnology Co., Ltd. (CN) | 2023-03-22 | — | — | EP | disclosed |
| EP-0272671-B1 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD (CH) | 1994-03-16 | — | — | EP | disclosed |
| US-5158936-A | Treating or prevention of tissue damage, inflammation, bone resporpption and muscular dystrophy | SYNTEX (U.S.A.) INC. (US) | 1992-10-27 | — | — | US | disclosed |
| US-5055451-A | Prevent tissue damage | SYNTEX INC. (US) | 1991-10-08 | — | — | US | disclosed |
| EP-0217804-B1 | ANALOGS OF SUBSTANCES P | ENICHEM S.p.A. (IT) | 1991-10-02 | — | — | EP | disclosed |
| EP-0272671-A2 | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors | SANDOZ LTD. (CH) | 1988-06-29 | — | — | EP | disclosed |
| EP-0217804-A1 | ANALOGS OF SUBSTANCES P. | ENICHEM SPA (IT) | 1987-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11622960-B2 | Microtubule polymerization inhibitor prodrugs and methods of using the same | TUBA1C, TUBB3, TUBB | CTSS 1741/4885CTSK 2183/4885CTSL 726/4885 |
| US-12433873-B2 | Microtubule polymerization inhibitor prodrugs and methods of using the same | TUBA1C, TUBB3, TUBB | CTSS 1741/4885CTSK 2183/4885CTSL 726/4885 |
| US-20230241034-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | TUBA1C, TUBB3, TUBB | CTSS 1741/4885CTSK 2183/4885CTSL 726/4885 |
| US-20260130889-A1 | MICROTUBULE POLYMERIZATION INHIBITOR PRODRUGS AND METHODS OF USING THE SAME | TUBB3, TUBB1, TUBB | CTSS 1380/4885CTSK 810/4885CTSL 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.